TP53 and colorectal carcinoma: As anti-p53 antibodies have been detected in cancer patients (including patients with CRC) and antibodies and T-cell receptors can recognize p53 mutants, vaccines targeting mutant p53 are being evaluated in clinical trials for the treatment of many different types of cancer, including CRC [194,195,196,197,198].